Latest news

• Biogen hands out $120m upfront for Remedy stroke drug

  The US biotech major is paying $120m upfront for rights to the drug, which is vying to be the first new treatment for ischaemic stroke since alteplase - still the only approved

• AZ's Brilinta disappoints in stroke trial

  Currently the only drug approved for the treatment of ischemic stroke is Genentech's tissue plasminogen activator (tPA) Activase (alteplase), although this remains a controversial therapy as the drug has an

• Daiichi Sankyo licenses clot-busting antibody

  as Genentech/Boehringer Ingelheim's Activase/Actilyse (alteplase), but Translational Sciences believes there is significant room for improvement.

• Lundbeck's desmoteplase flunks phase III stroke trial

  An older thrombolytic called alteplase (tPA) - sold by Genentech as Activase - is already approved to treat stroke, but remains a controversial therapy as the drug has an extremely narrow therapeutic window ... The drug is also easier to administer than